ScholarIQanswers from OpenAlex
Ranibizumab in neovascular age-related macular degeneration
PaperCitations, authors & open-access status
Ranibizumab in neovascular age-related macular degeneration is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Ranibizumab in neovascular age-related macular degeneration have?
ScholarIQcitation count
Ranibizumab in neovascular age-related macular degeneration has 223 citations in the OpenAlex counts ScholarIQ stores.
When was Ranibizumab in neovascular age-related macular degeneration published?
ScholarIQyear
Ranibizumab in neovascular age-related macular degeneration has 2006 year in the ScholarIQ index.
What is the open-access status of Ranibizumab in neovascular age-related macular degeneration?
ScholarIQoa status
Ranibizumab in neovascular age-related macular degeneration has gold oa status in the ScholarIQ index.
What is the DOI of Ranibizumab in neovascular age-related macular degeneration?
ScholarIQdoi
The DOI for Ranibizumab in neovascular age-related macular degeneration is on the source record.
What is the PMID of Ranibizumab in neovascular age-related macular degeneration?
ScholarIQpmid
The PMID for Ranibizumab in neovascular age-related macular degeneration is on the source record.
What is the OpenAlex record for Ranibizumab in neovascular age-related macular degeneration?
ScholarIQopenalex
The OpenAlex for Ranibizumab in neovascular age-related macular degeneration is on the source record.